1Medical Research/Tokushima University, Tokushima, Japan
2Japan Masters Athletics, Tokushima Division, Board, Tokushima, Japan
Corresponding Author: Hiroshi BANDO, MD, PhD, FACP ORCID iD
Address: Tokushima University /Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan.
Received date: 24 February 2021; Accepted date: 21 April 2021; Published date: 30 April 2021
Citation: Bando H. Trend for Clinical Use of Metabolic Associated Fatty Liver Disease (MAFLD). Asp Biomed Clin Case Rep. 2021 Apr 30;4(2):99-102.
Copyright © 2021 Bando H. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.
Keywords: Fatty Liver, Non-Alcoholic Fatty Liver Disease, Metabolic Associated Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Abbreviations: NAFLD: Non-Alcoholic Fatty Liver Disease; MAFLD: Metabolic Associated Fatty Liver Disease; NASH: Non-Alcoholic Steatohepatitis
The problems among obesity, diabetes mellitus (DM), fatty liver, metabolic dysfunction have been prevalent, and diagnostic criteria as non-alcoholic fatty liver disease (NAFLD) has been used in practice. When diagnosing NAFLD, to exclude other related liver diseases was necessary, including excessive alcohol intake. The international experts proposed the proper term from NAFLD to metabolic associated fatty liver disease (MAFLD). MAFLD criteria include the evidence of the presence of hepatic steatosis associated with three situations. They are obesity/overweight, presence of Type 2 DM (T2DM), or metabolic impaired function, which were studied in the light of pathophysiology, epidemiology, diagnosis and pharmacotherapy.